Anavex extends cash runway to three years as Alzheimer’s review continues
Anavex Life Sciences (NASDAQ:AVXL) reported a narrowed net loss and a robust cash position for its fiscal first quarter, providing the clinical-stage biotech with a three-year financial cushion as it contests a regulatory setback in Europe and prepares for pivotal U.S. filings.





-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)













